These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 2240363)
41. Immunization of Aotus monkeys with recombinant proteins of an erythrocyte surface antigen of Plasmodium falciparum. Collins WE; Anders RF; Pappaioanou M; Campbell GH; Brown GV; Kemp DJ; Coppel RL; Skinner JC; Andrysiak PM; Favaloro JM Nature; 1986 Sep 18-24; 323(6085):259-62. PubMed ID: 2429187 [TBL] [Abstract][Full Text] [Related]
42. A histidin alanine rich recombinant antigen protects Aotus monkeys from P. falciparum infection. Knapp B; Shaw A; Hundt E; Enders B; Küpper HA Behring Inst Mitt; 1988 Apr; (82):349-59. PubMed ID: 3044343 [TBL] [Abstract][Full Text] [Related]
43. Immunization with synthetic peptides of a Plasmodium falciparum surface antigen induces antimerozoite antibodies. Cheung A; Leban J; Shaw AR; Merkli B; Stocker J; Chizzolini C; Sander C; Perrin LH Proc Natl Acad Sci U S A; 1986 Nov; 83(21):8328-32. PubMed ID: 3534885 [TBL] [Abstract][Full Text] [Related]
44. Immunization of Aotus monkeys with Plasmodium falciparum blood-stage recombinant proteins. Herrera S; Herrera MA; Perlaza BL; Burki Y; Caspers P; Döbeli H; Rotmann D; Certa U Proc Natl Acad Sci U S A; 1990 May; 87(10):4017-21. PubMed ID: 2187200 [TBL] [Abstract][Full Text] [Related]
45. Plasmodium falciparum SERA protein peptide analogues having short helical regions induce protection against malaria. Cubillos M; Alba MP; Bermúdez A; Trujillo M; Patarroyo ME Biochimie; 2003 Jul; 85(7):651-7. PubMed ID: 14505820 [TBL] [Abstract][Full Text] [Related]
46. Antibody responses to Plasmodium falciparum sporozoite-, liver- and blood-stage synthetic peptides in migrant and autochthonous populations in malaria endemic areas. Ferreira-da-Cruz MF; Deslandes DC; Oliveira-Ferreira J; Montenegro-James S; Tartar A; Druilhe P; Daniel-Ribeiro CT Parasite; 1995 Mar; 2(1):23-9. PubMed ID: 9137641 [TBL] [Abstract][Full Text] [Related]
47. Safety and immunogenicity in volunteers of a recombinant Plasmodium falciparum circumsporozoite protein malaria vaccine produced in Lepidopteran cells. Herrington DA; Losonsky GA; Smith G; Volvovitz F; Cochran M; Jackson K; Hoffman SL; Gordon DM; Levine MM; Edelman R Vaccine; 1992; 10(12):841-6. PubMed ID: 1455910 [TBL] [Abstract][Full Text] [Related]
48. Induction of protective immunity to monoclonal-antibody-defined Plasmodium falciparum antigens requires strong adjuvant in Aotus monkeys. Siddiqui WA; Tam LQ; Kan SC; Kramer KJ; Case SE; Palmer KL; Yamaga KM; Hui GS Infect Immun; 1986 Apr; 52(1):314-8. PubMed ID: 3514459 [TBL] [Abstract][Full Text] [Related]
49. The development of molecular vaccines against malaria sporozoites. Ballou WR; Young JF; Cryz SJ; Sadoff JC Adv Exp Med Biol; 1989; 251():295-313. PubMed ID: 2692428 [No Abstract] [Full Text] [Related]
50. Peptides inducing short-lived antibody responses against Plasmodium falciparum malaria have shorter structures and are read in a different MHC II functional register. Patarroyo ME; Alba MP; Vargas LE; Silva Y; Rosas J; Rodríguez R Biochemistry; 2005 May; 44(18):6745-54. PubMed ID: 15865420 [TBL] [Abstract][Full Text] [Related]
51. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. BenMohamed L; Gras-Masse H; Tartar A; Daubersies P; Brahimi K; Bossus M; Thomas A; Druilhe P Eur J Immunol; 1997 May; 27(5):1242-53. PubMed ID: 9174617 [TBL] [Abstract][Full Text] [Related]
52. Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine. Pöltl-Frank F; Zurbriggen R; Helg A; Stuart F; Robinson J; Glück R; Pluschke G Clin Exp Immunol; 1999 Sep; 117(3):496-503. PubMed ID: 10469053 [TBL] [Abstract][Full Text] [Related]
54. Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria. Salcedo M; Barreto L; Rojas M; Moya R; Cote J; Patarroyo ME Clin Exp Immunol; 1991 Apr; 84(1):122-8. PubMed ID: 2015702 [TBL] [Abstract][Full Text] [Related]
55. Sporozoite malaria vaccine. Where do we stand? Nussenzweig V; Nussenzweig S Ann Parasitol Hum Comp; 1990; 65 Suppl 1():49-52. PubMed ID: 1702271 [TBL] [Abstract][Full Text] [Related]
56. Ability of recombinant or native proteins to protect monkeys against heterologous challenge with Plasmodium falciparum. Etlinger HM; Caspers P; Matile H; Schoenfeld HJ; Stueber D; Takacs B Infect Immun; 1991 Oct; 59(10):3498-503. PubMed ID: 1894356 [TBL] [Abstract][Full Text] [Related]
57. Antibody responses to a synthetic peptide-based malaria vaccine candidate: influence of sequence variants of the peptide. Etlinger HM; Renia L; Matile H; Manneberg M; Mazier D; Trzeciak A; Gillessen D Eur J Immunol; 1991 Jun; 21(6):1505-11. PubMed ID: 2044658 [TBL] [Abstract][Full Text] [Related]
58. Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates. Flueck C; Frank G; Smith T; Jafarshad A; Nebie I; Sirima SB; Olugbile S; Alonso P; Tanner M; Druilhe P; Felger I; Corradin G Vaccine; 2009 May; 27(20):2653-61. PubMed ID: 19428875 [TBL] [Abstract][Full Text] [Related]
59. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Egan JE; Hoffman SL; Haynes JD; Sadoff JC; Schneider I; Grau GE; Hollingdale MR; Ballou WR; Gordon DM Am J Trop Med Hyg; 1993 Aug; 49(2):166-73. PubMed ID: 8357078 [TBL] [Abstract][Full Text] [Related]
60. Malaria vaccines: results of human trials and directions of current research. Cattani JA Exp Parasitol; 1989 Feb; 68(2):242-7. PubMed ID: 2647511 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]